Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.13M Buy
+506,934
New +$1.91M ﹤0.01% 6408
2026
Q1
– Sell
-48,385
Closed -$91.4K – 12870
2025
Q4
$91.4K Buy
48,385
+7,869
+19% +$14.5K ﹤0.01% 11709
2025
Q3
$79.8K Buy
+40,516
New +$82.9K ﹤0.01% 11976
2024
Q2
– Sell
-12,995
Closed -$36.6K – 14139
2024
Q1
$36.6K Buy
+12,995
New +$40.5K ﹤0.01% 12484
2023
Q2
– Sell
-12,805
Closed -$18.1K – 14256
2023
Q1
$18.1K Buy
+12,805
New +$21.8K ﹤0.01% 13137
2022
Q1
– Sell
-16,753
Closed -$134K – 13461
2021
Q4
$134K Buy
+16,753
New +$172K ﹤0.01% 12407
2021
Q2
– Sell
-22,371
Closed -$402K – 13577
2021
Q1
$402K Buy
+22,371
New +$510K ﹤0.01% 10164

Other funds holding ADAG

Citadel Advisors's ADAG Position: Q2 2026 in Review

Citadel Advisors opened a new position in Adagene (ADAG) in Q2 2026: 506,934 shares worth $2.13M. The stake represents ﹤0.01% of the portfolio and ranks #6408 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ADAG as recently as Q4 2025.

Citadel Advisors first reported a position in ADAG in Q1 2021 and has held it in 7 quarters since. 35 funds tracked by Wall St. Rank hold ADAG as of Q2 2026.

  • Citadel Advisors held 506,934 shares of Adagene worth $2.13M as of Q2 2026.
  • Adagene was a new Citadel Advisors position in Q2 2026.
  • Adagene made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6408 holding.
  • Citadel Advisors first reported a position in Adagene in Q1 2021 and has held it in 7 quarters since.
  • 35 funds tracked by Wall St. Rank held Adagene as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.